

Title: Antibody Drug Conjugates for Cancer Therapy



Speaker

Paul G. Polakis, Ph.D.

Staff Scientist and Director, Cancer Targets, Genentech, Inc.



Chairman

Mitsuaki Yoshida, Ph.D.

Director, The Cancer Chemotherapy Center of Japanese Foundation of Cancer Research (JFCR)
Professor Emeritus, The University of Tokyo, Japan

Paul G. Polakis, Ph.D.

CURRENT POSIOTION:

2005-present Staff Scientist and Director, Cancer Targets, Genentech, Inc.

EDUCATION:

Ph.D., 1984, Biochemistry, Department of Biochemistry, Michigan State University

PUBLICATIONS:

1. Identification and immunotherapeutic targeting of antigens induced by chemotherapy. *Nat. Biotechnol.* 2006 24:205-9.
2. Shulewitz M, Soloviev I, Wu T, Koeppen H, Polakis P, Sakanaka C. 2006. Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer. *Oncogene.* 25:4361-9. Polakis, P. The many ways of Wnt in cancer. 2007. *Curr Opin Genet Dev.* 17; 45-
3. Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, Luis E, Zhong F, Bheddah S, Koeppen H, Gogineni A, Ross S, Polakis P, Mallet W. 2007. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. *Cancer Res.* 67:4924-32.

4. DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P, Rubinfeld B. 2007. The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. *Cancer Res.* 67; 5371-9.
5. Wang BE, Wang XD, Ernst JA, Polakis P, Gao WQ. 2008. Regulation of epithelial branching morphogenesis and cancer cell growth of the prostate by Wnt signaling. *PLoS ONE* 3 (5):e2186.
6. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH,
7. Polakis P, Mallet W. 2008. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. *Nat Biotechnol.* 26:925-32.
8. Morrell NT, Leucht P, Zhao L, Kim JB, ten Berge D, Ponnusamy K Carre AL, Dudek H, Zachlederova M, McElhaney M, Brunton S, Gunzner J, Callow M, Polakis P, Costa M, Zhang XM, Helms JA, Nusse R. 2008. Liposomal packaging generates Wnt protein with in vivo biological activity. *PLoS ONE.* 3(8):e2930.
9. Polakis P. 2008. Formation of the blood-brain barrier: Wnt signaling seals the deal. *J Cell Biol.* 183:371-3.
10. Strickland LA, Ross J, Williams S, Ross S, Romero M, Spencer S, Erickson R, Sutcliffe J, Verbeke C, Polakis P., van Bruggen N, Koeppen H. 2009. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. *J Pathol.* 218:380-90.
11. Liu BY, Soloviev I., Chang P., Lee J., Huang X., Zhong C., Ferrara N., Polakis P., Sakanaka C. 2010 Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cells. *PLoS One.* 5(1):e8611.
12. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hilaragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX. 2010. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. *Clin Cancer Res.* 16; 4769-4778.
13. Gong Y, Bourhis E, Chiu C, Stawicki S, DeAlmeida VI, Liu BY, Phamluong K, Cao TC, Carano RA, Ernst JA, Solloway M, Rubinfeld B, Hannoush RN, Wu Y, Polakis P, Costa M. 2010. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. *PLoS One* ;5(9):e12682.
14. Asundi J, Reed C, Arca J, McCutcheon K, Ferrando R, Clark S, Luis E, Tien J, Firestein R, Polakis P. 2011. An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma. *Clin Cancer Res.* 17:965-75.
15. Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, Liu PS, Bheddah S, Tao J, Lill JR, Hongo JA, Davis D, Kirkpatrick DS, Polakis P, Costa M. 2011. Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. *PLoS One* ;6(7):e22595.
16. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR. 2012. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. *Nat Biotechnol.* 30:184-189.
17. Liu BY, Soloviev I, Huang X, Chang P, Ernst JA, Polakis P, Sakanaka C. 2012. Mammary tumor regression elicited by Wnt signaling inhibitor requires IGFBP5. *Cancer Res.* 72:1568-78.
18. Polakis P. 2012 Wnt Signaling in Cancer. *Cold Spring Harb Perspect Biol.* 1;4(5) Review.
19. Chen Y, Chalouni C, Tan C, Clark R, Venook R, Ohri R, Raab H, Firestein R, Mallet W, Polakis P. 2012. The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma. *J Biol Chem.* 2012 May 21. [Epub ahead of print].
20. Polakis P. Drugging wnt signaling in cancer. 2012. *EMBO J.* 2012 May 22..126. [Epub ahead of print]

IAAO2012 Title of the Talk:

Antibody Drug Conjugates for Cancer Therapy

ABSTRACT:

Antibody drug conjugates share the common feature of targeting internalizing cell surface proteins with an antibody covalently linked to a highly potent cytotoxic compound. In principal, this enables higher local exposure of the tumor to the drug than that permissible by systemic delivery of the free drug. Recent advances in this technology have resulted in some very encouraging objective clinical responses and numerous ADCs are now in various stages of development. I will discuss some of the challenges associated with research and development of antibody drug conjugates including target selection, the impact of linker chemistry, target- independent toxicity and drug resistance. In addition, I will present some evidence for the potential benefit of combining ADCs targeting melanocytic antigens with MAP kinase pathway inhibitors in the treatment of melanoma.